MedPath

Kidpower Camp - Structured Games or Playgroup

Not Applicable
Completed
Conditions
Anxiety Disorders
Interventions
Behavioral: Playgroup
Behavioral: Structured games
Registration Number
NCT04960813
Lead Sponsor
Columbia University
Brief Summary

Clinically significant anxiety affects 20% of preschoolers and can become chronic, leading to depression, substance abuse, school-drop out and even suicide. To reduce anxiety and prevent its sequelae, clinically affected children must be effectively treated early. Available interventions for clinically anxious preschoolers are effective for some, but not all children, with as many as 50% of 4-7 year olds continuing to meet criteria for an anxiety disorder after treatment.

This trial aims to help learn how Camp Kidpower, trainings using either structured games or a playgroup, may lower anxiety in preschool age children. Playing these games and learning that kids can do it, can teach kids how to keep going when they are feeling anxious. To find out if Kidpower works by helping kids stay in charge of their behaviors and emotions, the study will look at parts of the brain as well as behaviors related to effortful control and fear, before and after training.

The study hypothesizes that Kidpower will produce greater increases in Error-related negativity (ERN), Interchannel Phase Synchrony (ICPS) and effortful control (EC) behaviors than in the Playgroup control.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
158
Inclusion Criteria
  1. Children between ages 4 -5.99 years at time of consent
  2. Children that have a primary clinical diagnosis of separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, panic disorder, and/or obsessive-compulsive disorder
  3. Written informed consent by a parent/legal guardian and verbal assent from participant
  4. Fluent in English
Exclusion Criteria
  1. History of head injury
  2. History of serious medical or neurological illness
  3. History of post-traumatic stress disorder (PTSD)
  4. History of major depressive disorder (MDD)
  5. Current psychotherapy or behavioral interventions
  6. History of Neurodevelopmental delay, autism spectrum disorder (ASD), or intellectual disability
  7. Currently taking medications that affect central nervous system functioning
  8. Primary clinical diagnosis is selective mutism or specific phobia
  9. Recent history of physically aggressive behaviors that have caused harm to other children
  10. Sibling of a child who has participated or is currently participating in this protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Kidpower - PlaygroupPlaygroupPlaygroup camp
Kidpower - Structured GamesStructured gamesStructured Games Camp.
Primary Outcome Measures
NameTimeMethod
Change in Error Related Negativity (ERN)Pre-treatment (baseline) and post-treatment assessments (approximately 4-6 weeks)

The error-related negativity is a neurophysiological signal, measured via electroencephalogram (EEG), considered to reflect a dorsal anterior cingulate cortex (ACC) response to errors. For this study the ERN will be measured at electrode site FCz as the downward (negative voltage) deflection of the EEG signal that occurs 50-100 msec after error commission on the Zoo Task. Scores are measured continuously (no established minimum or maximum) . Higher scores reflect greater neural capacity for effortful control.

Change in National Institutes of Health (NIH) Toolbox Effortful Control (EC) Composite ScalePre-treatment (baseline) and post-treatment assessments (approximately 4-6 weeks)

The NIH Toolbox EC Composite Scale will be comprised of children's standardized scores reflecting accuracy and reaction time on two computerized tasks: the Flanker inhibitory control and attention task and the Dimensional Change Card Sort (DCCS) test of set-shifting function. An NIH Toolbox EC Composite score will be based on factor loadings for each task derived from a factor analysis of scores across both Toolbox tasks. Scores are measured continuously (no established minimum or maximum) . Higher scores reflect greater behavioral capacity for effortful control.

Change in Clinical Global Impressions -Severity and Improvement ScalesPre-treatment (baseline) and post-treatment assessments (approximately 4-6 weeks)

The Clinical Global Impressions (CGI) is an observer rated scale used to assess anxiety severity (CGI-S) and pre- to post-treatment improvement in anxiety (CGI-I). Ratings for both use a 7-point scale, from 1 "normal" to 7 "among the most severely ill" for CGI-S and 1 ("very much improved") to 7 ("very much worse") for CGI-I.

Secondary Outcome Measures
NameTimeMethod
Change in Anxiety Disorders Interview Schedule - Parent Version (ADIS-P)Pre-treatment (baseline) and post-treatment assessments (approximately 4-6 weeks)

ADIS-P is a semi-structured clinical interview administered to parents about their child to assess Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnoses where anxiety is a component. Severity of symptoms is rated by interviewers on a scale from none (=0) to very severe (=8), with clinician severity rating (CSR) ≥ 4 indicating presence of diagnosis. Changes in CSR of the primary (i.e., most severe at baseline) anxiety diagnosis from pre to post intervention will be assessed.

Change in Spence Preschool Anxiety Scale (Spence PAS)Pre-treatment (baseline) up to post-treatment assessments (approximately 4-6 weeks)

The Spence PAS is a validated instrument for the measurement of parent report of anxiety symptoms in young children. Spence PAS scores will provide a continuous rating of anxiety symptoms from 0 to 112; high scores reflect greater anxiety.

Trial Locations

Locations (4)

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

Michigan State University

🇺🇸

East Lansing, Michigan, United States

Columbia University

🇺🇸

New York, New York, United States

New York State Psychiatric Institute

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath